Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Eaby, Beth
24  Ergebnisse:
Personensuche X
?
1

A proposed EGFR inhibitor dermatologic adverse event-specif..:

Lacouture, Mario E. ; Maitland, Michael L. ; Segaert, Siegfried...
Supportive Care in Cancer.  18 (2010)  4 - p. 509-522 , 2010
Link: https://doi.org/10.1007/..
 
?
2

Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Pati..:

Malhotra, Binu ; Evans, Tracey ; Weiss, Jared...
Clinical Lung Cancer.  11 (2010)  3 - p. 192-197 , 2010
Link: https://doi.org/10.3816/..
 
?
3

Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Ca..:

Weiss, Jared ; Eaby, Beth ; Stevenson, James...
Journal of Thoracic Oncology.  5 (2010)  5 - p. 667-672 , 2010
Link: https://doi.org/10.1097/..
 
?
4

Expert Consensus on the Management of Erlotinib-Associated ..:

Thatcher, Nicholas ; Nicolson, Marianne ; Groves, Richard W....
The Oncologist.  14 (2009)  8 - p. 840-847 , 2009
Link: https://doi.org/10.1634/..
 
?
5

Validation and Psychometric Assessment of a Short Clinical ..:

Molassiotis, Alexander ; Coventry, Peter A. ; Stricker, Carrie T....
Journal of Pain and Symptom Management.  34 (2007)  2 - p. 148-159 , 2007
Link: https://doi.org/10.1016/..
 
?
6

Epidermal Growth Factor Receptor Inhibitor–Associated Cutan..:

Lynch Jr., Thomas J. ; Kim, Ed S. ; Eaby, Beth...
The Oncologist.  12 (2007)  5 - p. 610-621 , 2007
Link: https://doi.org/10.1634/..
 
?
7

Nursing Considerations with EGFR Inhibitors in NSCLC:

, In: Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners,
Turner, Michelle M. ; Eaby-Sandy, Beth - p. 17-25 , 2019
Link: https://doi.org/10.1007/..
 
?
8

Nursing Considerations with ALK and ROS1 Inhibitors in NSCL:

, In: Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners,
Eaby-Sandy, Beth - p. 27-37 , 2019
Link: https://doi.org/10.1007/..
 
?
9

Introduction:

, In: Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners,
Eaby-Sandy, Beth - p. 1-2 , 2019
Link: https://doi.org/10.1007/..
 
?
10

Targeted Therapies in Lung Cancer: Management Strategies fo..:

Davies, Marianne ; Eaby-Sandy, Beth - 1st ed. 2019 . , 2019
Link: https://doi.org/10.1007/..
 
?
11

Osimertinib: A Novel Dermatologic Adverse Event Profile in ..:

Chu, Chia-Yu ; Choi, Jennifer ; Eaby-Sandy, Beth..
The Oncologist.  23 (2018)  8 - p. 891-899 , 2018
Link: https://doi.org/10.1634/..
 
?
12

P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) ..:

Bagley, Stephen ; Kothari, Shawn ; Aggarwal, Charu...
Journal of Thoracic Oncology.  12 (2017)  1 - p. S1289 , 2017
Link: https://doi.org/10.1016/..
 
?
13

NU04.03 Where are we With TKI Toxicities:

Eaby-Sandy, Beth
Journal of Thoracic Oncology.  12 (2017)  1 - p. S205-S206 , 2017
Link: https://doi.org/10.1016/..
 
?
14

P3.02c-069 Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR..:

Bagley, Stephen ; Kothari, Shawn ; Aggarwal, Charu...
Journal of Thoracic Oncology.  12 (2017)  1 - p. S1318 , 2017
Link: https://doi.org/10.1016/..
 
?
15

Pretreatment neutrophil-to-lymphocyte ratio as a marker of ..:

Bagley, Stephen J. ; Kothari, Shawn ; Aggarwal, Charu...
Lung Cancer.  106 (2017)  - p. 1-7 , 2017
Link: https://doi.org/10.1016/..
 
1-15